Cellceutix Releases Positive Results From KM-391 Study

Reportedly, the samples were evaluated in different parameters like: brain plasticity, serotonin levels and behavioral function. These parameters were selected as important indicators of the effect needed to successfully treat autism.

In the study, the compound has been given orally over 90 days to groups of rats at two dosage levels. The study result suggested that in each level KM-391 has shown improvement in groups when compared to ‘no treatment’ group and ‘active control’ (fluoxetine) group in different parameters.

George Evans, CEO of Cellceutix, said: “We are extremely excited about the data on KM-391 and the potential for the compound in this area of urgent medical need. Diagnoses of autism are rising dramatically and the disease takes a terrible toll on families. There is a critical need for new treatments for autism and we are pleased to be part of the effort to find them.”

Krishna Menon, chief scientific officer of Cellceutix, said: “Research on autism has been difficult because there has been no reliable animal model. Fortunately, we were able to tap into some cutting edge research to find a promising model for our study.”